Read our COVID-19 research and news.

Webinar Technology

Deciphering the cell cycle: The role of cell cycle control in cancer

This webinar is brought to you by the Science/AAAS Custom Publishing Office

Deciphering the cell cycle: The role of cell cycle control in cancer

08 July 2020

12:00 p.m. ET

Register now!


Please note that this webinar was postponed from 8 April to 8 July 2020.

A fundamental hallmark of cancer is uncontrolled cell division. In an effort to understand this process, researchers have focused on characterizing the signaling proteins that govern the regulation of the cell cycle. Specific cyclin dependent kinases (CDKs) and their activating cyclin subunits are desirable therapeutic targets because they regulate a cell’s transition through different phases and checkpoints in the cycle, providing opportunities to block dysregulated cell division and therefore block tumor growth. In recent years, researchers have seen success with FDA-approved treatments that target CDK4/6 at the G1/S checkpoint of the cell cycle in estrogen receptor-positive and HER2-negative breast cancers. Many clinical trials are ongoing, not only to test new drugs, but also to examine the effects of combinatorial therapies on various cancer types. In their presentations, our speakers will discuss the intricate interactions between key cell-cycle proteins and how therapeutic interventions can target their activity to fight common cancers.

During the webinar viewers will:

  • Hear about exciting advancements in understanding how CDKs regulate cell cycle control
  • Discover how new CDK inhibitors can be used in combination with other therapeutics to target cancer
  • Learn about similarities and differences in critical cell cycle signaling pathways in different cancer types
  • Have the opportunity to ask questions during the live broadcast.

This webinar will last for approximately 60 minutes

You can also view part 1 of this series.

Speaker bios

Yue Xiong, Ph.D.

University of North Carolina
Chapel Hill, NC

Dr. Xiong completed his undergraduate training at Fudan University in Shanghai, China, and his graduate studies at the University of Rochester in New York. After completing his postdoctoral training at Cold Spring Harbor Laboratory (also in New York), he joined the University of North Carolina (UNC) at Chapel Hill, where he is currently the William R. Kenan Jr. Distinguished Professor in the Department of Biochemistry and Biophysics. His research interests are broadly focused on the mechanisms of cell proliferation and cancer development. More specifically, he seeks to understand the regulation of mammalian G1 cyclins and cyclin-dependent kinase (CDK) inhibitor genes and their role in cancer (especially as potential targets for cancer diagnosis and drug development); the action of E3 ubiquitin ligases and control of the cell cycle and p53 by the ubiquitin pathway; and how altered metabolic enzymes impact epigenetic control and contribute to tumorigenesis. He was honored with the American Association for Cancer Research Gertrude B. Elion Cancer Research Award in 1999 and the UNC Hyman L. Battle Distinguished Cancer Research Award in 2011. In 2012, Dr. Xiong was elected as a fellow of the American Association for the Advancement of Science.

Gary Schwartz, M.D.

Herbert Irving Comprehensive Cancer Center
New York, NY

Dr. Schwartz is professor of medicine and chief of the Division of Hematology and Medical Oncology at the Columbia University Irving Medical Center (CUIMC) and deputy director of the Herbert Irving Comprehensive Cancer Center (HICCC). He is a nationally recognized translational investigator, whose research aims to understand the mechanisms underlying cell cycle and cell death, in order to improve the effectiveness of currently available treatments, with a focus on the development of novel therapies for patients with a wide range of malignancies, including gastrointestinal cancers, sarcoma, and melanoma. Prior to his recruitment to Columbia in 2014, he was chief of the Melanoma and Sarcoma Service at Memorial Sloan Kettering Cancer Center. He has worked on several review committees for the U.S. National Institutes of Health and has served on the editorial boards of various scientific journals, including as associate editor for the Journal of Clinical Oncology and Clinical Cancer Research. Dr. Schwartz is the recipient of many awards and honors, including the Jeannik M. Littlefield–AACR Grant in Metastatic Colon Cancer, the Nobility in Science Award from the Sarcoma Foundation of America, and the Ewig Award for recognition of outstanding teaching of house staff and fellows at CUIMC.

Sean Sanders, Ph.D.

Washington, DC

Dr. Sanders did his undergraduate training at the University of Cape Town, South Africa, and his Ph.D. at the University of Cambridge, UK, supported by the Wellcome Trust. Following postdoctoral training at the National Institutes of Health and Georgetown University, Dr. Sanders joined TranXenoGen, a startup biotechnology company in Massachusetts working on avian transgenics. Pursuing his parallel passion for writing and editing, Dr. Sanders joined BioTechniques as an editor, before joining Science/AAAS in 2006. Currently, Dr. Sanders is the Director and Senior Editor for Custom Publishing for the journal Science and Program Director for Outreach.

Sponsored by

Get webinar alerts

For more information on upcoming webinars, recorded sessions and more, sign up for webinar alerts.

Sign up here